These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35245945)

  • 1. The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists.
    Visser C; Biedermann JS; Nierman MC; van der Meer FJM; Gulpen AJW; Moors YCF; Cannegieter SC; Lijfering WM; Kruip MJHA;
    Thromb Haemost; 2022 Mar; 122(3):377-385. PubMed ID: 35245945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
    Beinema MJ; van der Meer FJ; Brouwers JR; Rosendaal FR
    J Thromb Haemost; 2016 Mar; 14(3):479-84. PubMed ID: 26712475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists.
    Visser C; Yousefi A; Nierman MC; Huisman MV; Gulpen AJW; van Ommen CH; Kruip MJHA;
    Thromb Res; 2023 Aug; 228():121-127. PubMed ID: 37321159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study.
    Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM
    Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin use decreases coagulation in users of vitamin K antagonists.
    van Rein N; Biedermann JS; Bonafacio SM; Kruip MJ; van der Meer FJ; Lijfering WM
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1441-1447. PubMed ID: 27709253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort.
    Maagdenberg H; Bierings MB; van Ommen CH; van der Meer FJM; Appel IM; Tamminga RYJ; de Boer A; Maitland-van der Zee AH
    J Thromb Haemost; 2018 Jan; 16(1):116-124. PubMed ID: 29108090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients.
    Kooistra HA; Veeger NJ; Khorsand N; Kluin-Nelemans HC; Meijer K; Piersma-Wichers M
    Thromb Haemost; 2015 Apr; 113(4):881-90. PubMed ID: 25518854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists.
    de Koning MLY; Fischer K; de Laat B; Huisman A; Ninivaggi M; Schutgens REG
    J Thromb Haemost; 2017 May; 15(5):868-875. PubMed ID: 28296129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study.
    van Miert JHA; Veeger NJGM; Ten Cate-Hoek AJ; Piersma-Wichers M; Meijer K
    PLoS One; 2020; 15(7):e0235639. PubMed ID: 32649714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of glucose-lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self-controlled register study.
    Stage TB; Pottegård A; Henriksen DP; Christensen MM; Højlund K; Brøsen K; Damkier P
    J Thromb Haemost; 2016 Jan; 14(1):129-33. PubMed ID: 26559049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of administering preprocedural VITamin K on the international normalized ratio in patients anticoagulated with ACEnocoumarol (VITKACE-study): a prospective cohort study.
    Bijkerk S; Lourens HJ; Mares WGN; van Kampen CA; van der Veen MJ; Adriaansen HJ; Ponfoort ED; Festen B; Westendorp GW; Rovers JMP; Groot GMC; Bootsma HR; Amelung LM; Bins S; Velders G; Bemelmans RHH
    J Thromb Haemost; 2024 Jul; 22(7):1847-1856. PubMed ID: 38580096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtherapeutic Anticoagulation Control under Treatment with Vitamin K-Antagonists-Data from a Specialized Coagulation Service.
    Prochaska JH; Hausner C; Nagler M; Göbel S; Eggebrecht L; Panova-Noeva M; Arnold N; Lauterbach M; Bickel C; Michal M; Hardt R; Espinola-Klein C; Lackner KJ; Münzel T; Wild PS
    Thromb Haemost; 2019 Aug; 119(8):1347-1357. PubMed ID: 31183847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
    Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
    Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up.
    Corrochano M; Jiménez B; Millón J; Gich I; Rambla M; Gil E; Caparrós P; Macho R; Souto JC
    BMC Cardiovasc Disord; 2020 Apr; 20(1):166. PubMed ID: 32276619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to optimal dosing of vitamin K antagonists.
    Witt DM
    Semin Thromb Hemost; 2012 Oct; 38(7):667-72. PubMed ID: 22893509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices.
    Nassif ME; LaRue SJ; Raymer DS; Novak E; Vader JM; Ewald GA; Gage BF
    Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27154497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF.
    Goto S; Goto S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Haas S; Parkhomenko A; Oto A; Misselwitz F; Turpie AGG; Verheugt FWA; Fox KAA; Gersh BJ; Kakkar AK
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):301-309. PubMed ID: 31821482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists?
    Steib A; Barre J; Mertes M; Morel MH; Nathan N; Ozier Y; Treger M; Samama CM
    J Thromb Haemost; 2010 Mar; 8(3):499-503. PubMed ID: 19912513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.
    van Rein N; Lijfering WM; Bos MH; Herruer MH; Vermaas HW; van der Meer FJ; Reitsma PH
    PLoS One; 2016; 11(12):e0164485. PubMed ID: 27935941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.